| Company Announcements: (reported by the Company) |
No items found
|
| Elevator Pitch: | A new Australian biotech company, Resseptor Therapeutics (‘Resseptor’), has launched with an initial AU$2.25 million investment to develop new therapies targeting autoimmune diseases and cancer. The funding round was led by leading university research commercialisation specialist IP Group Australia and will support the company through pre-clinical proof-of-concept. |
| Category: | Health & biotech |
| URL: | https://www.ipgroupanz.com/resseptor-therapeutics |
| Operational Status: | Active |
| ASX Listing Code (if applicable): | |
| Year of Commencement: | 2023 |
| Address: | Brisbane, Queensland, Australia |
| State: | Queensland |
| Overseas Operations: | No |
| Twitter: | |
| Facebook: | |
| Linkedin: | |
| Founders: |
No items found
|
| Awards won: | |
